Balanced but Constrained Upside: Hold Rating on Biogen as Modest Litifilimab Data Meet Rising Lupus Competition

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Biogen, retaining the price target of $190.00.

Terence Flynn has given his Hold rating due to a combination of factors related to Biogen’s lupus program and its broader risk‑reward profile. The Phase 2 AMETHYST data for litifilimab in cutaneous lupus show a statistically meaningful improvement in skin disease activity versus placebo and a generally manageable safety profile, but effect sizes appear modest and seem to plateau by Week 16, with key secondary endpoints not powered for definitive statistical conclusions.

At the same time, litifilimab faces a competitive landscape that includes Merck KGaA’s enpatoran, which has shown stronger relative responses in a Phase 2 CLE trial, and AstraZeneca’s Saphnelo, which is pursuing label expansion in the same space. With pivotal readouts for litifilimab only expected from 2026 onward and Morgan Stanley modeling risk‑adjusted 2035 sales at roughly $700 million with a 50% probability of success, Flynn sees a balanced outlook where potential upside is tempered by execution, timing, and competitive risks, supporting a neutral (Hold) stance on BIIB shares.

According to TipRanks, Flynn is a 5-star analyst with an average return of 9.8% and a 56.21% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Moderna, and Johnson & Johnson.

In another report released yesterday, UBS also maintained a Hold rating on the stock with a $185.00 price target.